- Report
- March 2024
- 238 Pages
Global
From €7685EUR$7,950USD£6,606GBP
- Report
- November 2020
- 241 Pages
Global
From €3079EUR$3,185USD£2,646GBP
€4399EUR$4,550USD£3,781GBP
- Report
- January 2019
- 35 Pages
Global
From €967EUR$1,000USD£831GBP
Avycaz is a brand of antibiotics used to treat a variety of bacterial infections. It is a combination of ceftazidime, an antibiotic, and avibactam, a beta-lactamase inhibitor. Avycaz is used to treat complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired bacterial pneumonia. It is also used to treat infections caused by certain Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Avycaz is a relatively new antibiotic on the market, having been approved by the U.S. Food and Drug Administration in 2015. It is manufactured by Allergan, a subsidiary of Pfizer, and is available in both intravenous and oral formulations. Other companies that produce antibiotics similar to Avycaz include Merck, AstraZeneca, and GlaxoSmithKline. Show Less Read more